IQVIA’s second-quarter sales growth produced no additional operating profit: a $93 million increase in combined business-segment profit was fully offset by higher corporate expenses, depreciation and amortization, and restructuring costs. Revenue rose 8.7% to $4.368 billion, while operating profit remained $506 million. Operating margin—the share of sales left after operating expenses—fell from 12.6% to 11.6%, a decline of 1.0 percentage point. For this healthcare services provider, converting customer work into profit matters as much as winning contracts. 10-Q, income statement, p. 3; segment reconciliation, p. 26
Dollar amounts below use M for millions and B for billions. Percentage changes, margins and other calculated comparisons use the reported figures.
1. Buybacks Reduced Equity While Debt Increased
IQVIA ended June with a smaller equity cushion—the accounting value of assets remaining after liabilities—and more debt, despite earning a first-half profit.
1-1. Acquired Assets Still Dominate the Balance Sheet
The table highlights the size of goodwill and intangible assets relative to cash and physical assets.
| Item ($M) | Dec. 31, 2025 | June 30, 2026 | Change |
|---|---|---|---|
| Cash and cash equivalents | 1,980 | 1,909 | −3.6% |
| Receivables and unbilled services, net | 3,400 | 3,345 | −1.6% |
| Property and equipment, net | 533 | 547 | +2.6% |
| Identifiable intangible assets, net | 4,962 | 4,749 | −4.3% |
| Goodwill | 16,616 | 16,604 | −0.1% |
| Total assets | 29,944 | 29,881 | −0.2% |
| Total liabilities | 23,314 | 23,580 | +1.1% |
| Total equity, including minority interests | 6,630 | 6,301 | −5.0% |
Goodwill represents acquisition value beyond separately identified net assets. Together with identifiable intangible assets, such as customer relationships and technology, it totals $21.353B, making future acquired-business earnings important to asset values. Receivables declined, but collections are not the only explanation: IQVIA also sells customer invoices to financial institutions. Inventory is not separately reported. 10-Q, p. 5; Notes 3–4
1-2. About a Third of Debt Principal Comes Due by December 2028
Debt principal—the amount borrowed before deductions for financing costs—increased from $15.800B to $16.081B. Scheduled repayments total $5.442B from June-end through December 2028, or 33.8% of principal. These calendar-year maturity totals do not identify the exact amount due over the following three years. The filing lists individual borrowing rates but no overall average interest rate. 10-Q, Note 7, p. 14
Operating obligations differ from borrowed money. Payables and accrued expenses fell from $3.751B to $3.608B, while unearned income—customer billings ahead of recognized revenue—rose from $2.118B to $2.281B. Operating lease assets, representing rights to use leased property, were $304M versus $290M; separately presented noncurrent lease liabilities, covering payments due beyond the near term, were $242M versus $225M. 10-Q, p. 5
1-3. Retained Profit Could Not Offset Repurchases
Retained earnings, or accumulated profits kept in the business, rose from $7.425B to $7.955B. Common stock and additional paid-in capital increased from $11.378B to $11.496B. However, the deduction for repurchased shares grew from $11.357B to $12.316B, and accumulated other comprehensive losses—accounting losses recorded outside net income—widened from $943M to $964M. These changes reduced parent-company equity from $6.503B to $6.171B. The repurchased shares remain treasury stock, meaning shares held by the company rather than canceled. 10-Q, p. 5
2. Sales Expanded Faster Than Consolidated Profit
Operating margin fell even though both businesses grew.
2-1. The Quarter Earned Less Profit per Sales Dollar
Compare profit with revenue within each period; H1 covers January through June, while Q2 covers April through June. Diluted earnings per share (EPS) spreads profit over the average share count, including potential additional shares from stock awards and similar instruments.
| Item ($M except margins and EPS) | Q2 2025 | Q2 2026 | H1 2025 | H1 2026 |
|---|---|---|---|---|
| Revenue | 4,017 | 4,368 | 7,846 | 8,519 |
| Operating profit | 506 | 506 | 1,002 | 1,020 |
| Operating margin | 12.6% | 11.6% | 12.8% | 12.0% |
| Net income attributable to IQVIA | 266 | 256 | 515 | 530 |
| Parent net income / revenue | 6.6% | 5.9% | 6.6% | 6.2% |
| Diluted earnings per share ($) | 1.54 | 1.53 | 2.94 | 3.14 |
IQVIA earned about $11.60 in operating profit per $100 of quarterly sales, down from $12.60. H1 revenue grew 8.6%, but operating profit grew just 1.8%. The ratio of those growth rates was about 0.21: operating profit grew roughly one-fifth as fast as revenue. This describes the period’s operating leverage—how quickly operating profit changed relative to sales. It does not predict the profit effect of future sales growth. 10-Q, p. 3; calculations from table inputs
H1 parent profit rose 2.9%, while diluted average shares fell from 175.3M to 168.6M. Holding profit constant, the smaller share count would increase EPS by roughly 4.0%, explaining why EPS grew faster than profit. Quarterly parent profit fell 3.8%, with higher interest expense and tax expense among the pressures below operating profit. 10-Q, p. 3
For historical context, annual figures show that revenue growth already outpaced net profit before this quarter.
| Item ($M except margins) | FY2023 | FY2024 | FY2025 | Annualized change, 2023–2025 |
|---|---|---|---|---|
| Revenue | 14,984 | 15,405 | 16,310 | 4.3% |
| Operating profit | 1,977 | 2,202 | 2,182 | 5.1% |
| Operating margin | 13.2% | 14.3% | 13.4% | — |
| Net income attributable to IQVIA | 1,358 | 1,373 | 1,360 | 0.1% |
| Parent net income / revenue | 9.1% | 8.9% | 8.3% | — |
These three annual observations span two compounding years, not three. Annualized change equals (FY2025 / FY2023)^(1/2) − 1; comparisons between full-year and interim margins should allow for seasonality. 2025 10-K, consolidated income statement, p. 70
2-2. Costs Outside the Segments Absorbed Their $93M Improvement
Combined quarterly segment profit rose from $852M to $945M. But corporate and unallocated expenses increased from $38M to $84M, depreciation and amortization from $276M to $292M, and restructuring from $32M to $63M. Those increases exactly consumed the $93M segment improvement. Segment profit excludes these costs and therefore is not consolidated operating profit. Depreciation and amortization spread the cost of physical and intangible assets over their useful lives. 10-Q, segment reconciliation, p. 26
Compensation and reimbursed client expenses drove higher service costs; compensation also increased administrative expenses. The filing does not quantify how much of the cost base stays fixed versus changes with business activity. Adding back only restructuring produces quarterly operating profit of $569M versus $538M. This is an author-calculated measure outside generally accepted accounting principles, not established recurring earnings: management expects restructuring to continue into the following year. 10-Q, pp. 23–24; Note 11
3. Better Cash Generation Still Fell Short of Buybacks
First-half cash generation improved, but repurchases exceeded cash left after capital spending.
Read the final row alongside repurchases, rather than treating all operating cash as available for shareholders. Cash-flow rows cover January through June; June-end cash is a balance at a single date, and its change column compares June 2026 with June 2025.
| Item ($M) | H1 2025 | H1 2026 | Change ($M) |
|---|---|---|---|
| Operating cash flow | 1,011 | 1,176 | +165 |
| Investing cash flow | −651 | −577 | +74 |
| Financing cash flow | −113 | −647 | −534 |
| June-end cash | 2,039 | 1,909 | −130 |
| Property, equipment and software purchases | 293 | 325 | +32 |
| Free cash flow: operating cash less purchases above | 718 | 851 | +133 |
Cash fell $71M during H1 2026, from $1,980M at December-end to $1,909M at June-end; the $130M decline in the table is the year-over-year comparison. 10-Q, pp. 5–6
Operating cash divided by consolidated net income, including earnings attributable to minority owners, rose from 1.96 times ($1,011M/$515M) to 2.21 times ($1,176M/$533M). Cash exceeded profit partly because $580M of depreciation and amortization and $160M of share compensation reduced reported profit without equivalent current-period cash payments. Receivables and customer billing balances added $239M, while other operating balances consumed $263M. Together, those operating-balance changes used $24M of cash, compared with $100M a year earlier, helping explain the improvement in cash generation. These timing effects prevent the ratio from serving as a simple test of earnings reliability. 10-Q, p. 6
For FY2023–FY2025, the same ratio was 1.58, 1.98 and 1.95 times, using operating cash of $2,149M, $2,716M and $2,654M. Corresponding consolidated net income was $1,358M, $1,373M and $1,361M. 2025 10-K, p. 73
Invoice-sale proceeds increased from $327M to $364M, helping accelerate cash collection. Capital purchases equaled 3.8% of H1 revenue ($325M/$8,519M); the filing does not split spending to maintain existing operations from spending to expand them. Buybacks of $950M exceeded free cash flow of $851M by $99M, before $200M spent on acquisitions, net of cash acquired. Debt issuance less debt and finance-lease repayments supplied $388M ($1,758M−$1,370M), before debt issuance costs; revolving borrowings and repayments offset each other. 10-Q, p. 6; Note 3
4. Clinical Revenue Grew, While Backlog Increased Modestly Since December
Clinical activity increased, but contracted work awaiting delivery grew only modestly over the first half. Backlog reflects both new work won and existing work converted into revenue, so its net change alone does not measure new-contract growth.
Research & Development Solutions revenue rose from $2.366B to $2.575B in Q2, driven by clinical-service and laboratory-testing volumes. Backlog increased only about 0.6%, calculated from the rounded reported balances of $34.0B at December-end and $34.2B in June. Management expects $9.2B to become revenue within twelve months; this is an expectation, not guaranteed sales. Prior segment comparisons were restated to reflect the business reorganization. 10-Q, pp. 26–28
The earnings release adds an important distinction: Q2 net new bookings rose 19% year-over-year to $3.15B. The reported book-to-bill ratio of 1.22 means net new contracted work was about $1.22 for each dollar of segment revenue recognized during the quarter. Stronger quarterly bookings can therefore coexist with modest growth in the backlog balance since December. IQVIA Q2 2026 earnings release
Commercial Solutions revenue rose from $1.651B to $1.793B, supported by patient solutions and commercial engagement services. At unchanged exchange rates, consolidated quarterly revenue growth was 8.5%, close to reported growth of 8.7%. Currency translation therefore explains little of the quarter’s sales increase. 10-Q, pp. 23, 27
Legal exposure remains uncertain. Note 8 provides no quantified aggregate reasonably possible loss range and says some liabilities cannot be estimated. Management does not expect pending matters to have a material overall effect, but acknowledges that an adverse resolution could materially affect a particular period. 10-Q, Note 8, p. 16
5. Margin Recovery Must Accompany Revenue Growth
The next financial test is whether growing customer activity leaves more profit after corporate expenses, asset-cost charges and restructuring. Clinical volumes and commercial services supported expansion, but flat quarterly operating profit shows that higher sales alone were insufficient. Continued restructuring and debt servicing remain claims on earnings and cash.
Management nevertheless raised its full-year 2026 revenue outlook to $17.275B–$17.475B, citing stronger growth excluding acquisitions and currency effects, together with revised acquisition and currency contributions. It also raised its adjusted profit outlook. Those adjusted measures exclude specified expenses and differ from the reported operating profit analyzed here; the forecasts do not establish a recovery in reported margins. IQVIA Q2 2026 earnings release
Actual H1 spending on buybacks exceeded capital purchases and acquisitions combined, without establishing management’s permanent ranking of priorities. Repurchases can support EPS, but repeating spending above free cash flow would require other funding or lower cash balances. Stronger margins and cash generation would give IQVIA more room to fund investment and upcoming debt repayments.
Sources: SEC Form 10-Q, filed July 28, 2026, accession 0001628280-26-050211; FY2025 Form 10-K; IQVIA Q2 2026 earnings release, July 28, 2026. Calculated measures use the cited filings.
This analysis is based on filings submitted to the U.S. Securities and Exchange Commission and is provided for informational purposes only. It is not investment advice.